FIELD: chemistry.
SUBSTANCE: in new compounds with general formula (I): , R1 stands for a naphthyl group, which can be substituted with a halogen atom, W represents a bond, a equals 0, 1 or 2, X1 represents C1-4alkylene, which can be substituted with a hydroxy group, Y1 represents -C(O)-,A represents a piperazine ring or piperidine ring, X2 represents a bond, Y2 represents -C(O)-, -S(O)2- or -C(=NR7)- (where R7 represents a hydrogen atom), X3 represents C1-4alkylene, which can be substituted with a hydroxyl group, oxo group or C1-6alkyl group; or C2-4alkylene, which can be substituted with a C1-6alkyl group, where two alkyl groups can be bonded to each other forming, together with carbon atoms to which they are bonded, an aryl ring when X3 represents C2-4alkylene, substituted with two alkyl groups, Z3 represents -N(R4)- or a bond (where R4 represents a hydrogen atom, C1-6alkyl group, which can be substituted with a hydroxy group or methoxy group, or acyl group), represents a single or double bond, where if represents a single bond, then Z1 represents -C(R2)(R2')-, -N(R2)- or -O- and Z2 represents C(R3)(R3')-, -N(R3)-, -O- or a bond (under the condition that, when Z2 represents -O-, then Z is different from -O-), and when represents a double bond, then Z1 represents -C(R3)= or a nitrogen atom and Z2 represents =C(R3)- or a nitrogen atom, each of R2, R2', R3 and R3' represents a hydrogen atom or C1-6alkylene. The invention also relates to salts of the given new compounds. The invention also relates to compounds, chosen from the group, to pharmaceutical compositions, to use of compounds in sub-paragraph 1 or 2, to prevention or treatment methods, as well as to the method of obtaining compounds in paragraph 1.
EFFECT: obtaining new biologically active compounds, which inhibit activated factor X of blood clotting and have anticoagulation activity and antithrombotic activity.
33 cl, 46 ex, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
PEPTIDE COMPOUNDS | 2001 |
|
RU2281955C2 |
PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | 2017 |
|
RU2796400C2 |
CYCLOALKANE-1,3-DIAMINE DERIVATIVE | 2019 |
|
RU2793247C2 |
CONDENSED 4-OXOPYRIMIDINE DERIVATIVE | 2005 |
|
RU2358969C2 |
NOVEL PIPERIDINE DERIVATIVES | 2006 |
|
RU2417985C2 |
DERIVATIVES OF DOLASTATIN 10 | 2002 |
|
RU2296750C2 |
DERIVATIVES OF DIAMINES | 2002 |
|
RU2319699C2 |
PYRIDOPYRIMIDINE INHIBITORS CDK2/4/6 | 2017 |
|
RU2726115C1 |
DIAMINE DERIVATIVES | 2002 |
|
RU2314303C2 |
ARYLCARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | 2003 |
|
RU2340605C2 |
Authors
Dates
2009-07-20—Published
2005-05-20—Filed